CC BY-NC-ND 4.0 · Endosc Int Open 2018; 06(05): E513-E517
DOI: 10.1055/s-0044-102097
Original article
Owner and Copyright © Georg Thieme Verlag KG 2018

Novel temperature-controlled RFA probe for treatment of blocked metal biliary stents in patients with pancreaticobiliary cancers: initial experience

Manu K. Nayar
HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
,
Kofi W. Oppong
HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
,
Noor L.H. Bekkali
HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
,
John S. Leeds
HPB Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom
› Author Affiliations
Further Information

Publication History

submitted 07 August 2017

accepted after revision 19 January 2018

Publication Date:
18 April 2018 (online)

Abstract

Background and study aims Radiofrequency ablation (RFA) is used to treat blocked biliary stents in patients with pancreaticobiliary (PB) tumors with varying results. We report our experience with a novel temperature-controlled probe for treatment of blocked metal stents.

Patients and methods Patients with histologically proven PB cancers and a blocked biliary stents were treated using ELRATM electrode (Taewoong Medical) under fluoroscopic guidance. Demographics, clinical outcome, stricture diameter improvements, complications and mortality at 30 days were prospectively recorded.

Results Nine procedures were performed on seven patients (4 male, 3 female); mean age 65.33 (range 56 – 82 years). Mean stricture diameter prior to RFA was 1.13 mm (SD ± 0.54) and 4.42 mm (SD ± 1.54) following RFA (P < 0.0001). Five of seven patients (71 %) required additional stents to ensure optimal drainage. There were no procedure-related complications. Mean follow-up was 193.55 days (range 31 – 540) and three of nine patients (33 %) died due to terminal cancer.

Conclusion These are the first reported data on use of a temperature-controlled RFA catheter in humans to treat blocked metal biliary stents. The device is safe but further randomized trials are required to establish the efficacy and survival benefits of this probe.

 
  • References

  • 1 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-1229
  • 2 Martin 2nd R. Management of locally advanced pancreatic cancer. Surg Clin North Am 2016; 96: 1371-1389
  • 3 O’Brien S, Hatfield AR, Craig PI. et al. Three year follow up of self-expanding metal stents in the endoscopic palliation of long-term survivors with malignant biliary obstruction. Gut 1995; 36: 618-621
  • 4 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80: 794-804
  • 5 Kallis Y, Phillips N, Steel A. et al. Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit. Dig Dis Sci 2015; 60: 3449-3455
  • 6 Sharaiha RZ, Natov N, Glockenberg KS. et al. Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures: is there an added benefit?. Dig Dis Sci 2014; 59: 3099-3102
  • 7 Sharaiha RZ, Sethi A, Weaver KR. et al. Impact of radiofrequency ablation on malignant biliary strictures: results of a collaborative registry. Dig Dis Sci 2015; 60: 2164-2169
  • 8 Dutta AK, Basavaraju U, Sales L. et al. Radiofrequency ablation for management of malignant biliary obstruction: a single-center experience and review of the literature. Expert Rev Gastroenterol Hepatol 2017; 7: 1-6
  • 9 Kadayifci A, Atar M, Forcione DG. et al. Radiofrequency ablation for the management of occluded biliary metal stents. Endoscopy 2016; 48: 1096-1101
  • 10 Cho JH, Lee KH, Kim JM. et al. Safety and Efficacy of a novel endobiliary radiofrequency ablation catheter (ELRA®) in a swine model. Gastrointest Endosc 2015; 81: AB350
  • 11 Alvarez-Sánchez MV, Napoléon B. Review of endoscopic radiofrequency in biliopancreatic tumours with emphasis on clinical benefits, controversies and safety. World J Gastroenterol 2016; 22: 8257-8270
  • 12 Knavel EM, Brace CL. Tumor ablation: common modalities and general practices. Tech Vasc Interv Radiol 2013; 16: 192-200
  • 13 Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 2001; 48: 359-367
  • 14 Shah DR, Green S, Elliot A. et al. Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol 2013; 5: 71-80
  • 15 Rhim H, Dodd GD, Chintapalli KN. et al. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics 2004; 24: 41-52
  • 16 Kallis Y, Phillips N, Steel A. et al. Analysis of Endoscopic Radiofrequency Ablation of Biliary Malignant Strictures in Pancreatic Cancer Suggests Potential Survival Benefit. Dig Dis Sci 2015; 60: 3449-3455
  • 17 Roque J, Ho SH, Reddy N. et al. Endoscopic ablation therapy for biliopancreatic malignancies. Clin Endosc 2015; 48: 15-19